Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus
Award amount
$149,997Program and phase
STTR · Phase IAward year
2018Award details
- Awarding agency
- Department of Defense
- Branch
- Office for Chemical and Biological Defense
- Recipient company
- EVRYS BIO LLC
- Proposal award date
- 2018-09-25
- Contract end date
- 2019-03-25
- UEI
- TM98GAF3Z6Q6
- Solicitation number
- 2018.0
- Topic code
- CBD18A-002
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure
- A single antiviral to treat multiple opportunistic infections
- Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure
- A single antiviral to treat multiple opportunistic infections
- SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Marburg Virus Prophylactic Medical Countermeasure
- Marburg Virus Prophylactic Medical Countermeasure
- Virus-Like Particle Based pan-Marburgvirus Vaccine
- Marburg Virus Prophylactic Medical Countermeasure
- Marburg Virus Prophylactic Medical Countermeasure
Research funding history
10 SBIR/STTR records share this UEI (2014–2024). Reported award amounts total $12,255,385. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense